Earnings Alerts

Centene Corp (CNC) Earnings: Maintains FY Adjusted EPS Forecast, Set to Present at Barclays Healthcare Conference

  • Centene is maintaining its Full Year Adjusted Earnings Per Share (EPS) forecast.
  • The company still sees an adjusted EPS above $6.70.
  • The estimated EPS is $6.72.
  • Centene will present at the Barclays 26th Annual Global Healthcare Conference.
  • The conference will take place on Tuesday, March 12, 2024, at 8:00 a.m. EDT.
  • The company’s stock has received 12 buy ratings, 8 hold ratings, and 0 sell ratings.
  • A conference call is scheduled for 8:30 a.m. New York time on April 26.

A look at Centene Corp Smart Scores

FactorScoreMagnitude
Value4
Dividend1
Growth4
Resilience3
Momentum4
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation, a multi-line managed care organization, has a promising long-term outlook according to the Smartkarma Smart Scores. With a score of 4 in both Value and Growth, the company is expected to perform well in terms of financial stability and potential for growth. This is supported by the fact that Centene provides Medicaid and Medicaid-related programs, which are in high demand and have a stable revenue stream. Additionally, the company offers specialty services such as behavioral health and nurse triage, which further diversify its business and contribute to its growth potential.

However, Centene scores lower in Dividend and Resilience with scores of 1 and 3 respectively. This means that the company may not be as strong in terms of dividend payouts and may face some challenges in the face of market volatility. Nevertheless, Centene still receives a high score of 4 in Momentum, indicating that it has strong momentum and is performing well in the current market. Overall, Centene Corporation is a well-established and diverse company with a positive outlook for the future.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars